CLINICAL_TRIALS
ClinicalTrials.gov record update
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05263817
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:46.305273+00:00
- Published At
- 2022-03-03T00:00:00+00:00
- Record Updated At
- 2022-03-03
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["POEMS Syndrome", "Amyloidosis", "Autoimmune Hemolytic Anemia", "Vasculitis"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-03-03"- protocolSection.identificationModule.nctId
"NCT05263817"- protocolSection.identificationModule.officialTitle
"A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["EARLY_PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.